Cargando…

Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients

The coronavirus disease 19 (COVID-19) pandemic has infected tens of millions across the world, but there is a significant gap in our understanding about COVID-19 in the hematopoietic stem transplant (HSCT) recipient population. Prolonged viral shedding is frequently observed with severe acute respir...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Alice, Rodriguez, Tulio E., Beck, Eric T., Relich, Ryan F., Udeoji, Dioma U., Petrak, Robert, Chundi, Vishnu V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834336/
https://www.ncbi.nlm.nih.gov/pubmed/34308401
http://dx.doi.org/10.1016/j.cpccr.2021.100057
_version_ 1783642260148060160
author Han, Alice
Rodriguez, Tulio E.
Beck, Eric T.
Relich, Ryan F.
Udeoji, Dioma U.
Petrak, Robert
Chundi, Vishnu V.
author_facet Han, Alice
Rodriguez, Tulio E.
Beck, Eric T.
Relich, Ryan F.
Udeoji, Dioma U.
Petrak, Robert
Chundi, Vishnu V.
author_sort Han, Alice
collection PubMed
description The coronavirus disease 19 (COVID-19) pandemic has infected tens of millions across the world, but there is a significant gap in our understanding about COVID-19 in the hematopoietic stem transplant (HSCT) recipient population. Prolonged viral shedding is frequently observed with severe acute respiratory syndrome coronavirus-2 (SARSCoV-2), but studies suggest viral loads decline 10 days after symptom onset. Current CDC guidance suggests that severely ill and immunocompromised hosts are no longer infectious after 20 days from symptom onset. Cycle threshold (Ct) values are inversely proportional to the viral load and are used to detect SARS-CoV-2 RNA concentration. Specimens with reverse transcriptase PCR (RT-PCR) Ct values > 33–34 have been associated with inability to culture virus, and have been used as a surrogate for diminished infectivity. We report two cases of  allogeneic peripheral blood stem cell transplant (PBSCT) recipients who had prolonged durations of infectivity with SARSCov-2, based on culture positivity and persistently low Ct values for greater than 50 days.
format Online
Article
Text
id pubmed-7834336
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-78343362021-01-26 Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients Han, Alice Rodriguez, Tulio E. Beck, Eric T. Relich, Ryan F. Udeoji, Dioma U. Petrak, Robert Chundi, Vishnu V. Current Problems in Cancer: Case Reports Article The coronavirus disease 19 (COVID-19) pandemic has infected tens of millions across the world, but there is a significant gap in our understanding about COVID-19 in the hematopoietic stem transplant (HSCT) recipient population. Prolonged viral shedding is frequently observed with severe acute respiratory syndrome coronavirus-2 (SARSCoV-2), but studies suggest viral loads decline 10 days after symptom onset. Current CDC guidance suggests that severely ill and immunocompromised hosts are no longer infectious after 20 days from symptom onset. Cycle threshold (Ct) values are inversely proportional to the viral load and are used to detect SARS-CoV-2 RNA concentration. Specimens with reverse transcriptase PCR (RT-PCR) Ct values > 33–34 have been associated with inability to culture virus, and have been used as a surrogate for diminished infectivity. We report two cases of  allogeneic peripheral blood stem cell transplant (PBSCT) recipients who had prolonged durations of infectivity with SARSCov-2, based on culture positivity and persistently low Ct values for greater than 50 days. The Authors. Published by Elsevier Inc. 2021-03 2021-01-16 /pmc/articles/PMC7834336/ /pubmed/34308401 http://dx.doi.org/10.1016/j.cpccr.2021.100057 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Han, Alice
Rodriguez, Tulio E.
Beck, Eric T.
Relich, Ryan F.
Udeoji, Dioma U.
Petrak, Robert
Chundi, Vishnu V.
Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients
title Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients
title_full Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients
title_fullStr Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients
title_full_unstemmed Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients
title_short Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients
title_sort persistent sars-cov-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834336/
https://www.ncbi.nlm.nih.gov/pubmed/34308401
http://dx.doi.org/10.1016/j.cpccr.2021.100057
work_keys_str_mv AT hanalice persistentsarscov2infectivitygreaterthan50daysinacaseseriesofallogeneicperipheralbloodstemcelltransplantrecipients
AT rodrigueztulioe persistentsarscov2infectivitygreaterthan50daysinacaseseriesofallogeneicperipheralbloodstemcelltransplantrecipients
AT beckerict persistentsarscov2infectivitygreaterthan50daysinacaseseriesofallogeneicperipheralbloodstemcelltransplantrecipients
AT relichryanf persistentsarscov2infectivitygreaterthan50daysinacaseseriesofallogeneicperipheralbloodstemcelltransplantrecipients
AT udeojidiomau persistentsarscov2infectivitygreaterthan50daysinacaseseriesofallogeneicperipheralbloodstemcelltransplantrecipients
AT petrakrobert persistentsarscov2infectivitygreaterthan50daysinacaseseriesofallogeneicperipheralbloodstemcelltransplantrecipients
AT chundivishnuv persistentsarscov2infectivitygreaterthan50daysinacaseseriesofallogeneicperipheralbloodstemcelltransplantrecipients